192 related articles for article (PubMed ID: 4031497)
21. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.
Ziccardi RJ
J Immunol; 1982 Jun; 128(6):2500-4. PubMed ID: 6281332
[TBL] [Abstract][Full Text] [Related]
22. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
23. Activation of the classical pathway of complement by tobacco glycoprotein (TGP).
Koethe SM; Nelson KE; Becker CG
J Immunol; 1995 Jul; 155(2):826-35. PubMed ID: 7608560
[TBL] [Abstract][Full Text] [Related]
24. Modified low density lipoproteins differentially bind and activate the C1 complex of complement.
Biró A; Thielens NM; Cervenák L; Prohászka Z; Füst G; Arlaud GJ
Mol Immunol; 2007 Feb; 44(6):1169-77. PubMed ID: 16938346
[TBL] [Abstract][Full Text] [Related]
25. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
[TBL] [Abstract][Full Text] [Related]
26. FN-C1q and C1 INH C1r-C1s complexes as indicators of complement activation in patients with chronic lymphocytic leukaemia.
Hidvégi T; Ermolin GA; Efremov EE; Dikov MM; Kurmanova LV; Vnashenkova GV; Merkulova MV; Kókai M; Panya A; Füst G
Immunol Lett; 1989 Jul; 22(1):1-6. PubMed ID: 2550362
[TBL] [Abstract][Full Text] [Related]
27. Interaction of fluid phase C1/C1q and macrophage membrane-associated C1q with gram-negative bacteria.
Clas F; Euteneuer B; Stemmer F; Loos M
Behring Inst Mitt; 1989 Jul; (84):236-54. PubMed ID: 2552981
[TBL] [Abstract][Full Text] [Related]
28. Human blood platelets possess specific binding sites for C1q.
Peerschke EI; Ghebrehiwet B
J Immunol; 1987 Mar; 138(5):1537-41. PubMed ID: 3492557
[TBL] [Abstract][Full Text] [Related]
29. Failure of oligosaccharide MOPC-104E IgM complexes to bind C1q and to activate C1.
Weiner EM
Biochem Int; 1987 Jul; 15(1):163-8. PubMed ID: 3502595
[TBL] [Abstract][Full Text] [Related]
30. Characterization of C1q by monoclonal antibodies.
Heinz HP; Loos M
Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
[TBL] [Abstract][Full Text] [Related]
31. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion.
Rossen RD; Michael LH; Hawkins HK; Youker K; Dreyer WJ; Baughn RE; Entman ML
Circ Res; 1994 Sep; 75(3):546-55. PubMed ID: 8062428
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.
Salvesen B; Nielsen EW; Harboe M; Saugstad OD; Mollnes TE
Mol Immunol; 2009 Feb; 46(4):688-94. PubMed ID: 18950866
[TBL] [Abstract][Full Text] [Related]
33. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
Schifferli JA; Steiger G; Schapira M
Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
[TBL] [Abstract][Full Text] [Related]
34. Complement activation, circulating C1q binding substances and inflammatory activity in rheumatoid arthritis: relations and changes on suppression of inflammation.
Berglund K; Laurell AB; Nived O; Sjoholm AG; Sturfelt G
J Clin Lab Immunol; 1980 Jul; 4(1):7-14. PubMed ID: 7463476
[TBL] [Abstract][Full Text] [Related]
35. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
Doekes G; van Es LA; Daha MR
J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
[TBL] [Abstract][Full Text] [Related]
36. C1q inhibits the expression of B lymphoblastoid cell line interleukin 1 (IL 1).
Habicht GS; Beck G; Ghebrehiwet B
J Immunol; 1987 Apr; 138(8):2593-7. PubMed ID: 3494080
[TBL] [Abstract][Full Text] [Related]
37. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes.
Chonn A; Cullis PR; Devine DV
J Immunol; 1991 Jun; 146(12):4234-41. PubMed ID: 2040798
[TBL] [Abstract][Full Text] [Related]
38. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
39. Effect of complement binding on a solid-phase immunometric TSH assay.
Käpyaho K; Tanner P; Weber T
Scand J Clin Lab Invest; 1989 May; 49(3):211-5. PubMed ID: 2662381
[TBL] [Abstract][Full Text] [Related]
40. Clq enhancement of IgG-dependent eosinophil-mediated killing of schistosomula in vitro.
Hamada A; Greene BM
J Immunol; 1987 Feb; 138(4):1240-5. PubMed ID: 3492545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
